214 related articles for article (PubMed ID: 28151036)
21. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
Singh SM; Wijeysundera HC
Curr Cardiol Rep; 2015 Aug; 17(8):61. PubMed ID: 26081245
[TBL] [Abstract][Full Text] [Related]
24. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
25. Real-life cost of vitamin K antagonist treatment in patients with non-valvular atrial fibrillation in France in 2013.
Dallongeville J; Ansolabehere X; Karusisi N; Maurel F; Van Ganse E; Le Heuzey JY
J Med Econ; 2017 Sep; 20(9):974-981. PubMed ID: 28682153
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.
Annavarapu S; Gandhi PK; Li Y; Arora P; Moretz C; Wang C; Sander SD; Andrews GA
J Comp Eff Res; 2018 Jul; 7(7):685-691. PubMed ID: 29808717
[TBL] [Abstract][Full Text] [Related]
27. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
28. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.
Kongnakorn T; Lanitis T; Annemans L; Thijs V; Goethals M; Marbaix S; Wautrecht JC
Clin Drug Investig; 2015 Feb; 35(2):109-19. PubMed ID: 25511639
[TBL] [Abstract][Full Text] [Related]
29. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
[TBL] [Abstract][Full Text] [Related]
30. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
31. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
32. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
33. Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study.
Chi NF; Wang Y; Chien LN; Chien SC; Ko Y
Med Care; 2018 May; 56(5):410-415. PubMed ID: 29578954
[TBL] [Abstract][Full Text] [Related]
34. Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
Vaughan Sarrazin MS; Jones M; Mazur A; Cram P; Ayyagari P; Chrischilles E
J Am Coll Cardiol; 2017 Jan; 69(3):360-362. PubMed ID: 28104077
[No Abstract] [Full Text] [Related]
35. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
J Med Econ; 2021; 24(1):550-562. PubMed ID: 33910464
[TBL] [Abstract][Full Text] [Related]
36. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
van Leent MW; Stevanović J; Jansman FG; Beinema MJ; Brouwers JR; Postma MJ
PLoS One; 2015; 10(8):e0135054. PubMed ID: 26241880
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
Wouters H; Thijs V; Annemans L
J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
[TBL] [Abstract][Full Text] [Related]
40. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
Bancroft T; Lim J; Wang C; Sander SD; Swindle JP
Clin Ther; 2016 Mar; 38(3):545-56.e1-6. PubMed ID: 26856927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]